About Affymetrix

Steve Fodor
1 | 2 | 3
1 | 2 | 3
1 | 2 | 3

企業のミッション

アフィメトリクスは、マイクロアレイのパイオニア的なメーカーとして、遺伝子解析テクノロジーの発展をリードしてまいりました。
そして現在、ゲノム解析からタンパク質や細胞の解析のための革新的な技術を提供するグローバルカンパニーへと変化しています。マイクロアレイで確固たる実績を積んだ基礎研究・探索市場を基盤とし、さらにトランスレーショナルリサーチからその臨床応用、アグリバイオやルーチン検査を支援するトータルソリューションをお届けすべく事業を展開しております。研究で得られた生物学的所見の、臨床やルーティン検査への展開を可能にする。それがアフィメトリクスのミッションです。

Management Team

Frank Witney, Ph.D.

President and Chief Executive Officer

Frank Witney, Ph.D.

Dr. Frank Witney brings more than 30 years of experience in leadership and innovation in life science research, products, and diagnostic and analytical instruments to Affymetrix. He previously served at Affymetrix as Executive Vice President and Chief Commercial Officer following Affymetrix' acquisition of Panomics Inc., a quantitative biology company he pioneered for six years as President and Chief Executive Officer. Prior to his return to Affymetrix, Dr. Witney was President and Chief Executive Officer of Dionex Corp., leading this ion and high performance liquid chromatography company to a hugely successful acquisition by Thermo Fisher Scientific, Inc.

Dr. Witney also served as President and Chief Operating Officer of Packard BioScience, overseeing global operations, research and development, manufacturing, and worldwide sales, achieving rapid growth in revenues and operating profits. When Packard was acquired by PerkinElmer Life Sciences, he became President of PerkinElmer's Drug Discover Tools division, managing the reagent and instrument business units for high-throughput screening, research products, genomics/proteomics and liquid handling automation.

Earlier in his management career, Dr. Witney held a series of positions at Bio-Rad Laboratories, most recently as Group Operations Manager of the Life Science Group, leading efforts to enter rapidly growing markets for proteomic and bioassay technologies.

Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a doctorate in molecular and cell biology from Indiana University.

Gavin Wood

Executive Vice President and Chief Financial Officer

Gavin Wood Executive Vice President and Chief Financial Officer

Mr. Wood became our Executive Vice President and Chief Financial Officer in 2013. Mr. Wood joined Affymetrix in 2006 and has held a number of financial roles, including Vice President, Finance, International Controller, responsible for Europe and Asia Pacific. Prior to joining Affymetrix, Mr. Wood held a number of positions at the Unipart Group of Companies, including Business Unit Controller and Business Process Manager for implementing major enterprise resource planning systems in North America. Mr. Wood is a Chartered Accountant who qualified with the London Accountancy Practice Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.

David Weber

Executive Vice President and Chief Commercial Officer

David Weber - Executive Vice President and Chief Commercial Officer, Affymetrix

Mr. Weber brings over 30 years of experience in the life science industry. In his role as Executive Vice President and Chief Commercial Officer, he oversees Global Sales, Customer Service and Support, Sales and Service Operations, and Marketing Communications. Mr. Weber previously served as President of MomentusBio, a life sciences consulting company, and prior to that as Vice President of the Life Science Practice for The Linus Group, a life sciences marketing firm. Earlier in his career, Mr. Weber was President and CEO of Eksigent Technologies; Senior Vice President of Marketing and Business Development for Stratagene; and President, Americas Region, for Amersham Biosciences (GE Healthcare). Mr. Weber is a Henry Rutgers Scholar with a B.S. in Biochemistry from Rutgers University and is a member of the Phi Beta Kappa Honor Society. He has also served on the Board of the Analytical Life Science and Diagnostics Association (ALDA), formerly known as the Analytical and Life Science Systems Association (ALSSA).

Andrew Last, Ph.D.

Executive Vice President and Chief Operating Officer

Andrew Last, Ph.D.

Dr. Last has 25 years of global experience in the life science, pharmaceutical, diagnostics, and agrochemical industries. In his role as Executive Vice President and Chief Operating Officer, he oversees all our Business Units, Global Operations, QA/QC, and Regulatory Functions. Dr. Last previously served as Vice President, Global Marketing and Strategic Planning at BD Biosciences Cell Analysis and General Manager of the company's Pharmingen Business. He has also held senior management positions at Applied Biosystems and Incyte Genomics. Dr. Last holds a Ph.D. in Agrochemical Specialization and a Master's degree in Bio-Aeronautics from Cranfield University in the UK and a Bachelor's degree in Biological Sciences from the University of Leicester, UK.

Siang Chin

Senior Vice President, General Counsel and Secretary

Siang Chin

Ms. Chin brings a broad range of legal experience to Affymetrix, having spent, collectively, approximately 20 years in private legal practice and public company management. Ms. Chin joined Affymetrix in 2007. Prior to joining Affymetrix, Ms. Chin practiced law at Shearman & Sterling and Slaughter and May. Ms. Chin received her law degree from the King's College, University of London.

Laurent Bellon, Ph.D.

Senior Vice President and General Manager, Genetic Analysis Business Unit

Laurent Bellon, Ph.D.

Dr. Bellon brings more than 20 years of experience in general management, business development, research and development, and operations in the life science and molecular diagnostics industries. In his role as Senior Vice President and General Manager of the Genetic Analysis Business Unit, he is responsible for Affymetrix' Clinical and Genotyping Strategic Marketing, Research and Development, and Global Operations. Dr. Bellon previously served at Affymetrix as Vice President of Genetic Analysis Research and Development, Program Management, Business Development, and Operations. Prior to joining Affymetrix in 2006, he held senior management positions at Applied Biosystems, Life Technologies, and Ribozyme Pharmaceuticals. Dr. Bellon holds a Ph.D. in Bio-Organic Chemistry and a Master's degree in Biochemistry, both from University Sciences et Techniques, Montpellier, France.

Daniel St. Louis, Ph.D.

Senior Vice President, Expression Business Unit

Daniel St. Louis, Ph.D.

Dr. St. Louis has 25 years of global experience in the life science and diagnostic industries. In his role as Senior Vice President of the Expression Business Unit, he is responsible for all Research and Development, Marketing, and Customer Service initiatives. Dr. St. Louis served as Vice President of Global Research and Development at eBioscience and joined Affymetrix through our acquisition of the company in 2012. He also held senior management positions at Invitrogen and BD Biosciences. Dr. St. Louis holds a Ph.D. in Biochemistry from the University of British Columbia and a B.S. in Biochemistry from McGill University.

Anthony Ward

Senior Vice President, eBioscience Business Unit

Anthony Ward eBioscience Business Unit, Affymetrix

Mr. Ward has over 25 years of global experience developing and commercializing products in the life science research products and diagnostic sectors. In his role as Senior Vice President and General Manager of the eBioscience Business Unit, he is responsible for the cell and protein analysis portfolio at Affymetrix. Mr. Ward served as Vice President of Commercial Operations at eBioscience from 2007 through the acquisition of the company by Affymetrix in 2012. Previously, he held positions of increasing responsibility at BD Biosciences in Research and Development, and he has over 18 years of experience in the marketing of research and diagnostic reagents and systems. Mr. Ward holds an MBA from Santa Clara University and a B.S. in Microbiology from Cal Poly San Luis Obispo.

Joe Magro

Vice President, Life Science Reagents Business Unit

Joe Magro – Vice President, Life Science Reagents Business Unit, Affymetrix

Mr. Magro has 15 years of experience in the healthcare and life science industries where he has served in leadership roles across sales, marketing, commercial operations, quality, and training and development. Prior to joining Affymetrix in 2008, Mr. Magro led Sales Operations for the Patient Monitoring business at GE Healthcare. During his 11 years with GE, Mr. Magro held a variety of management roles in sales, driving consistent revenue growth with a focus on customer satisfaction. He earned certification as a Six Sigma Black Belt while improving commercial effectiveness, training Green Belts, and mentoring process improvement projects across the commercial team. Mr. Magro earned his MBA from the Kelley School of Business at Indiana University and holds a BSE in Industrial and Operations Engineering from the University of Michigan.

Tracy Ting

Senior Vice President, Human Resources

Tracy Ting – Senior Vice President, Human Resources, Affymetrix

Ms. Ting joined Affymetrix in 2014 to lead the global Human Resources organization, bringing over 20 years of combined finance and HR expertise. Prior to joining Affymetrix, Ms. Ting served as Vice President of Human Resources and Compensation at Varian Medical Systems where she was instrumental in the creation of the company's talent management strategy and led the transformation of its global HR systems and processes. Ms. Ting brings significant global compensation, talent strategy, and HR operations experience from her 14 years at Varian, having contributed toward the company's growth from 1,900 to 6,500 employees. Prior to Varian, Ms. Ting worked at PricewaterhouseCoopers LLP (formerly Coopers & Lybrand LLP) in Los Angeles. Ms. Ting holds a Bachelor's degree in Communications Studies with an emphasis in Business Administration from the University of California, Los Angeles.

Directors

Stephen P.A. Fodor, Ph.D.

Affymetrix Founder and Chairman

Stephen P.A. Fodor, Ph.D. is our Founder and Chairman. Dr. Fodor has served as director since 1993. He served as Chief Executive Officer from 1997 to 2008 and as Chairman from 1999 to present. At various times between 1993 and 1997, Dr. Fodor served as President, Chief Operating Officer and Chief Technology Officer. Dr. Fodor was Vice President and Director of Physical Sciences at the Affymax Research Institute from 1989 to 1993. Dr. Fodor is the founder and Chief Executive Officer of Cellular Research, Inc. and serves as a Trustee of the Carnegie Institution of Science and as a member of the National Academy of Engineering. Dr. Fodor also serves on a variety of scientific advisory boards. The Board of Directors selected Dr. Fodor as a director nominee because he is the founder of the Company and our former Chief Executive Officer. The Board of Directors values Dr. Fodor’s extensive knowledge of the Company and our industry, his scientific vision and his perspective on emerging technologies and markets.

Frank Witney, Ph.D.

Affymetrix President and Chief Executive Officer

Frank Witney, Ph.D. has served as President, Chief Executive Officer and a director since July 2011. Dr. Witney served as President and Chief Executive Officer of Dionex Corporation from April 2009 to May 2011. Between December 2008 and April 2009, Dr. Witney served as our Executive Vice President and Chief Commercial Officer. Previously, Dr. Witney served as President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008. The Board of Directors selected Dr. Witney as a director nominee because the Board values Dr. Witney’s industry experience and his perspective as the Chief Executive Officer of the Company.

Nelson C. Chan

Chief Executive Officer (Retired)
Magellan Navigation, Inc.

Nelson C. Chan has served as a director since March 2010 and is the Chairman of the Audit Committee and a member of the Compensation Committee. Mr. Chan served as Chief Executive Officer of Magellan Navigation, Inc. from 2006 to 2008. From 1992 through 2006, Mr. Chan served in various senior management positions with SanDisk Corporation, including most recently as Executive Vice President and General Manager, Consumer Business. Mr. Chan is a member of the Board of Directors of Coinstar, Inc. and Synaptics Incorporated. The Board of Directors selected Mr. Chan as a director nominee because of his substantial experience with public and private companies, both as an executive and as a board member, and his expertise in building profitable technology companies. Mr. Chan also qualifies as a financial expert and serves as Chairman of the Audit Committee.

Gary S. Guthart, Ph.D.

President and Chief Executive Officer
Intuitive Surgical

Gary S. Guthart, Ph.D. has served as a director since May 2009 and is a member of the Compensation Committee. Dr. Guthart has served as the Chief Executive Officer of Intuitive Surgical, Inc. since January 2010. Dr. Guthart joined Intuitive Surgical, Inc. in April 1996, became Chief Operating Officer in 2006, and was promoted to President in 2007. Prior to joining Intuitive Surgical, Inc., Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formally Stanford Research Institute). Dr. Guthart serves on the Board of Directors of Intuitive Surgical, Inc. The Board of Directors selected Dr. Guthart as a director nominee because of his experience in the management of complex, high-growth businesses. The Board values Dr. Guthart’s contribution to the Company’s strategic planning and business development efforts and his insights as a member of the Compensation Committee.

Jami Dover Nachtsheim

Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing (Retired)
Intel Corporation

Jami Dover Nachtsheim has served as a director since March 2010 and is the Chairwoman of the Compensation Committee. Ms. Nachtsheim served in a variety of positions with Intel Corporation from 1980 until her retirement in 2000, most recently as Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim is a member of the Board of Directors of FEI Company and The Tech Museum of Innovation. The Board of Directors selected Ms. Nachtsheim as a director nominee because of her extensive experience in bringing high technology products to market and her service as a board member of numerous public and private organizations. The Board values the guidance she provides with respect to market strategies and her contributions as the Chairwoman of the Compensation Committee.

Robert H. Trice, Ph.D.

Senior Vice President, Strategy and Business Development (Retired)
Lockheed Martin Corporation

Robert H. Trice, Ph.D. has served as a director since 2006, is the Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee. Dr. Trice served as Senior Vice President for Business Development at Lockheed Martin Corporation from October 1998, and assumed additional duties as Senior Vice President for Strategy and Business Development at Lockheed Martin Corporation from March 2009 until his retirement in January 2011. The Board of Directors selected Dr. Trice as a director nominee because of his broad experience in government relationships (many of our large customers are government institutions) and his extensive background as a business development leader. The Board values his financial literacy and wide-ranging business competencies, which qualify him to serve on the Audit Committee and the Nominating and Corporate Governance Committee.

Robert P. Wayman

Executive Vice President and Chief Financial Officer (Retired)
Hewlett-Packard Company

Robert P. Wayman has served as a director since 2007, is our lead independent director and a member of the Audit Committee and the Nominating and Corporate Governance Committee. Mr. Wayman served as Executive Vice President and Chief Financial Officer of Hewlett-Packard Company from 1984 until his retirement in December 2006. Mr. Wayman also served as Interim Chief Executive Officer of Hewlett-Packard Company from February 2005 through March 2005 and served on the Board of Directors of Hewlett-Packard Company from February 2005 to March 2007 and from 1993 to 2002. Mr. Wayman has served as a director of CareFusion Corp. since 2009. The Board of Directors selected Mr. Wayman as a director nominee because of his broad-based financial expertise and business experience. The Board of Directors values Mr. Wayman’s background in finance and company operations, corporate governance and compliance, and the leadership that he has provided as the lead independent director and as a member of the Audit Committee and the Nominating and Corporate Governance Committee.

Back to Top >

Corporate History

First Microarray Prototype

アフィメトリクスは、新たな遺伝子解析技術を取り入れ、生活の質の革新に貢献しています。

現在までに24,000報を越える科学論文の発表に使われているマイクロアレイの技術を開拓し、さらに、発見、探索、検証、および遺伝子検査のための拡張性のある革新的なゲノム解析ツールと試薬のプロバイダーへと進化しています。Panomics社とUSB社の合併により、複数から単一の遺伝子のハイスループットな解析と、高い有用性の分子生物学用試薬をお客様に提供できるようになりました。現在では、全ゲノム解析のトータルソリューションの他、細胞およびタンパク質の解析研究用の幅広い製品を取り揃えています。
世界中の研究者がアフィメトリクスのテクノロジーを利用して、遺伝子が疾患において果たす役割、治療薬の有効性と安全性、そしてヒトの健康に影響するその他多くの因子に関する研究に成果をあげています。アフィメトリクスのテクノロジーは様々な革新的発見をもたらし、不妊、HIV、パーキンソン病、糖尿病、マラリア、癌といった疾患、その他多くの問題に関する科学界・医学界の研究を支えております。
私達は、遺伝情報の社会貢献に革命を起こすことをミッションとし、現在も、製品のポートフォリオの拡大、利便性のより高い遺伝子関連製品の開発、ならびに次世代テクノロジーの導入を通して、遺伝子解析分野における存在意義を高め続けています。
アフィメトリクスはこれまで、今日の遺伝子解析市場の形成に大きく貢献してまいりましたが、今後もさらにゲノム革命の推進に取り組み続け、あらゆる人が自らのDNAを理解することにより恩恵を受けられるよう努力してまいります。

沿 革

アフィメトリクスのGeneChip®テクノロジーは、1980年代後半にStephen P.A. Fodor博士率いる科学者チームによって発明されました。これは半導体の製造技術をコンビナトリアルケミストリーと組み合わせ、微小なガラスチップの上に多量の生物学的データを構築するという革新的な理論に基づいた技術です。この技術をもとにして1991年、Affymax, N.V.の1部門が設立されましたが翌年1992年、新会社アフィメトリクスとして独立・創業しました。カリフォルニア州サンタクララに本社をおき、1996年6月には新規に株式公開いたしました。

会社概要

研究用GeneChip®システムの販売を1994年に開始し、現在ではその製品を製薬、バイオテクノロジー、農業、診断薬、およびコンシューマ製品の関連企業、ならびに大学、政府機関、その他の非営利研究機関に直接販売しています。

買収

eBioscience, Inc.

2012年6月 株式非公開企業eBioscience Holding Company, Inc.(本社カリフォルニア州サンディエゴ)を買収しました。eBioscienceは免疫学やオンコロジー領域のフローサイトメトリーとイムノアッセイ用試薬のリーディングカンパニーで、ライフサイエンスの研究および診断向けに非常に多数の抗体やELISAおよびタンパク質の品揃えを有しています。

Panomics, Inc.

2008年11月、アフィメトリクスは株式非公開企業Panomics, Inc.(本社カリフォルニア州フレーモント)を買収しました。これにより、遺伝子、タンパク質および細胞解析といった、一連の強力なアッセイ製品を提供可能になりました。

True Materials Inc.

2008年7月、株式非公開企業True Materials Inc.(本社サンフランシスコ)を買収しました。この会社は、1万ものマーカーを同時分析できる技術を開発していました。

USB Corporation

2007年12月、株式非公開企業USB Corporation(本社オハイオ州クレーブランド)を買収しました。これにより、分子生物学および生化学試薬の幅広い製品ラインを提供可能になりました。100%子会社のAnatrace Inc.(膜タンパク質の抽出・精製用製品を製造)も買収対象となりました。

ParAllele BioScience Inc.

2005年10月、総合的遺伝子研究用に高い拡張性のあるテクノロジーを提供していた、株式非公開企業ParAllele BioScienceを買収しました。

Neomorphic, Inc.

2000年10月、コンピューターゲノミクス企業であった株式非公開企業Neomorphicを買収しました。

Genetic MicroSystems, Inc.

2000年2月、DNAアレイテクノロジーを専門とする機器製造の株式非公開企業Genetic MicroSystemsを買収しました。

特許

アフィメトリクスは多種多様な米国特許を取得しています。アフィメトリクス・ライセンスプログラムページ(http://www.affymetrix.com/about_affymetrix/legal/index.affx)から最新リストをご覧いただけます。

Back to Top >